Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, raw materials, and pharmaceutical preparations in China and internationally. The company's pharmaceutical intermediate products primarily includes 7-ACA, 6-APA, penicillin industrial salt, etc.; API products for anti-infection applications comprising azithromycin, amoxicillin, potassium clavulanate, ceftriaxone sodium, etc., as well as urine source biochemical products and other characteristic raw materials; pharmaceutical preparations, such as cardiovascular and cerebrovascular drugs that comprises enalapril maleate tablets and nifedipine controlled-release tablets; and anti-aging drugs, including cefuroxime axetil and cefuroxime sodium; and metabolic and endocrine drugs consist if methylprednisolone sodium succinate through injections. Its products portfolio covers systemic anti-infection, heart and brain blood vessels, anti-tumor and immunomodulators, central nervous system, hormones, genitourinary system, digestive tract and metabolism, respiratory system, and other therapeutic areas in various dosage forms, such as tablets, capsules, powder injections, small volume injections, granules, suspensions, suppositories, and ointments. The company also offers animal vaccines and general health products. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Shanghai, China. Address: No. 378, Jianlu Road, Shanghai, China, 200137